Cargando...

An Anti-Cancer Drug Candidate CYC116 Suppresses Type I Hypersensitive Immune Responses through the Inhibition of Fyn Kinase in Mast Cells

Mast cells are the most prominent effector cells of Type 1 hypersensitivity immune responses. CYC116 [4-(2-amino-4-methyl-1,3-thiazol-5-yl)-N-[4-(morpholin-4-yl)phenyl] pyrimidin-2-amine] is under development to be used as an anti-cancer drug, but the inhibitory effects of CYC116 on the activation o...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Biomol Ther (Seoul)
Autores principales: Park, Young Hwan, Kim, Hyun Woo, Kim, Hyuk Soon, Nam, Seung Taek, Lee, Dajeong, Lee, Min Bum, Min, Keun Young, Koo, Jimo, Kim, Su Jeong, Kim, Young Mi, Kim, Hyung Sik, Choi, Wahn Soo
Formato: Artigo
Lenguaje:Inglês
Publicado: The Korean Society of Applied Pharmacology 2019
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6513188/
https://ncbi.nlm.nih.gov/pubmed/30332888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4062/biomolther.2018.148
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!